ClinicalTrials.gg
CompletedNCT03444038Updated Feb 23, 2022Results posted

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

A Phase 2 interventional study of Valbenazine in Tourette Syndrome, sponsored by Neurocrine Biosciences. Completed at 37 sites in 2 countries. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
31st of 105
85 · median 33
Started
2018
with 11 others
Phase 2
26 of 139
4 open now
Registered
82nd of 139
by date
Lead sponsor
8 of 139
Neurocrine Biosciences

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 31st largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2018, is one of 26 in phase 2, and was the 82nd registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b, multicenter, open-label study to evaluate the safety and tolerability of optimized doses of NBI-98854 administered once daily for 24 weeks in pediatric subjects with Tourette Syndrome.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have participated in and completed Study NBI-98854-TS2003
  2. Have a clinical diagnosis of Tourette Syndrome (TS)
  3. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g. obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]), be on stable doses
  4. Be in good general health
  5. Adolescent subjects (12 to 18 years of age) must have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids and a negative alcohol screen
  6. Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month prior to screening
  2. Have a known history of long syndrome or cardiac arrhythmia
  3. Have a known history of neuroleptic malignant syndrome
  4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
  5. Have an allergy, , or intolerance to vesicular monoamine transporter 2 (VMAT2) inhibitors
  6. Have a blood loss ≥250 mL or donated blood within 56 days prior to baseline
  7. Have a known history of substance (drug) dependence, or substance or alcohol abuse
  8. Have a significant risk of suicidal or violent behavior
  9. Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Valbenazine

    Valbenazine administered once daily for up to 24 weeks

    Drug: Valbenazine

Interventions

  • vesicular monoamine transporter 2 (VMAT2) inhibitor

    Also known as: NBI-98854

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing. All qualifying TEAE are reported regardless of threshold.

    Time frame: Baseline through Week 24

07

Results

Posted Feb 23, 2022

Participant flow

Up to 120 male and female pediatric participants, 6 to 18 years of age, with a Diagnostic and Statistical Manual of Mental Disorders, 4th or 5th Editions (DSM-IV or -5) diagnosis of Tourette Syndrome, were planned to be enrolled. A total of 85 participants were enrolled and received at least 1 dose of study treatment.

Participant flow — Overall Study
MilestoneValbenazine
Started85
Completed56
Not completed29
Withdrew: Adverse event12
Withdrew: Withdrawal by subject7
Withdrew: Lost to follow-up1
Withdrew: Physician decision2
Withdrew: Lack of efficacy7

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

A TEAE is an adverse event not present prior to the initiation of study drug dosing, or is an already present event that worsens either in intensity or frequency following the initiation of study drug dosing. All qualifying TEAE are reported regardless of threshold.

Time frame:
Baseline through Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsValbenazine
Number of Participants With Treatment-emergent Adverse Events (TEAEs)71

Adverse events

Collected over From baseline up to Week 28.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valbenazine0/85 (0%)3/85 (3.5%)50/85 (58.8%)
Most frequent serious events
Most frequent serious events
EventValbenazine
Infected bitesInfections and infestations1/85
Cognitive disorderNervous system disorders1/85
Henoch-Schonlein purpuraSkin and subcutaneous tissue disorders1/85
Most frequent other events
Most frequent other events
EventValbenazine
SomnolenceNervous system disorders17/85
FatigueGeneral disorders11/85
SedationNervous system disorders10/85
NauseaGastrointestinal disorders9/85
HeadacheNervous system disorders9/85
IrritabilityGeneral disorders8/85
Abdominal pain upperGastrointestinal disorders5/85
DepressionPsychiatric disorders5/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)Valbenazine
Mean12.6 ± 2.6
Sex: Female, Male
Sex: Female, Male(Participants)Valbenazine
Female16
Male69
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Valbenazine
Hispanic or Latino25
Not Hispanic or Latino60
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Valbenazine
Race — American Indian or Alaska Native0
Race — Asian3
Race — Native Hawaiian or Other Pacific Islander1
Race — Black or African American6
Race — White72
Race — More than one race0
Race — Other3
08

Study locations

37 sites
  • Neurocrine Clinical Site
    Sun City, Arizona 85351, United States
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
  • Neurocrine Clinical Site
    San Diego, California 92108, United States
  • Neurocrine Clinical Site
    Santa Ana, California 92705, United States
  • Neurocrine Clinical Site
    Santa Clarita, California 91321, United States
  • Neurocrine Clinical Site
    New Haven, Connecticut 06510, United States
  • Neurocrine Clinical Site
    Boca Raton, Florida 33431, United States
  • Neurocrine Clinical Site
    Gulf Breeze, Florida 32561, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33013, United States
  • Neurocrine Clinical Site
    Orlando, Florida 32801, United States
  • Neurocrine Clinical Site
    Orlando, Florida 32803, United States
  • Neurocrine Clinical Site
    Saint Petersburg, Florida 33701, United States
  • Neurocrine Clinical Site
    Tampa, Florida 33614, United States
  • Neurocrine Clinical Site
    Chicago, Illinois 60634, United States
  • Neurocrine Clinical Site
    Naperville, Illinois 60563, United States
  • Neurocrine Clinical Site
    Iowa City, Iowa 52242, United States
  • Neurocrine Clinical Site
    Leawood, Kansas 66206, United States
  • Neurocrine Clinical Site
    Ann Arbor, Michigan 48105, United States
  • Neurocrine Clinical Site
    Bloomfield Hills, Michigan 48371, United States
  • Neurocrine Clinical Site
    Saint Louis, Missouri 63110, United States
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
  • Neurocrine Clinical Site
    Nashua, New Hampshire 03060, United States
  • Neurocrine Clinical Site
    Mount Arlington, New Jersey 07856, United States
  • Neurocrine Clinical Site
    Voorhees, New Jersey 08043, United States
  • Neurocrine Clinical Site
    Bronx, New York 10467, United States
  • Neurocrine Clinical Site
    New York, New York 10036, United States
  • Neurocrine Clinical Site
    Durham, North Carolina 27705, United States
  • Neurocrine Clinical Site
    Mason, Ohio 45040, United States
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Neurocrine Clinical Site
    Charleston, South Carolina 29414, United States
  • Neurocrine Clinical Site
    Dallas, Texas 75243, United States
  • Neurocrine Clinical Site
    Houston, Texas 77030, United States
  • Neurocrine Clinical Site
    Houston, Texas 77058, United States
  • Neurocrine Clinical Site
    San Antonio, Texas 78249, United States
  • Neurocrine Clinical Site
    Everett, Washington 98201, United States
  • Neurocrine Clinical Site
    Tacoma, Washington 98405, United States
  • Neurocrine Clinical Site
    San Juan, 00926, Puerto Rico
09

References and documents

Publications

  • Farber RH, Angelov A, Kim K, Carmack T, Thai-Cuarto D, Roberts E. Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Rev Neurother. 2021 Apr;21(4):393-404. doi: 10.1080/14737175.2021.1898948. Epub 2021 Apr 1. PubMed 33682568 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jul 2019, 17 months.

Results were first posted in Feb 2022, 2 years 7 months after primary completion. A results delay was requested in Jan 2020.

Of 19 phase 2 interventional studies under Tourette Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2018
First posted
Feb 23, 2018
StartActual
Feb 8, 2018
Primary completionActual
Jul 12, 2019
CompletionActual
Jul 12, 2019
Results delay requested
Jan 30, 2020
Results first posted
Feb 23, 2022
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03444038
Responsible party
Sponsor
First posted
Feb 23, 2018
Start date
Feb 8, 2018
Primary completion
Jul 12, 2019
Completion
Jul 12, 2019
Results posted
Feb 23, 2022
Last update
Feb 23, 2022

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion